Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

Status unconfirmed · Phase 2/Phase 3

Conditions studied: Lymphoma

In brief

RATIONALE: Diagnostic imaging procedures, such as radiolabeled monoclonal antibodies, may improve the ability to detect the residual disease in patients who have been treated for non-Hodgkin's lymphoma. PURPOSE: Phase II/III trial to study the effectiveness of monoclonal antibodies in detecting residual disease in patients who have been treated for non-Hodgkin's lymphoma.

Key facts

Study ID

NCT00003338

Run by

Gilead Sciences

People needed

60

Starts

1997-03-01

Last updated by the study team

2021-08-16

Who can join

Age: 16 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cedars-Sinai Medical Center — Los Angeles, California, United States
• Marlene & Stewart Greenebaum Cancer Center, University of Maryland — Baltimore, Maryland, United States
• Nuclear Physicians Ltd. — Cuyahoga Falls, Ohio, United States
• University of Texas- Houston Medical School — Houston, Texas, United States
• Innsbruck Universitaetsklinik — Innsbruck, Austria
• Istituto Europeo Di Oncologia — Milan, Italy
• Lund University Hospital — Lund, Sweden
• Centre Hospitalier Universitaire Vaudois — Lausanne, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.